Nurix Therapeutics reported a net margin of -990.10% for the quarter ended May 2026. These financial ratios cover 28 quarters of results from Aug 2019 through May 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Aug2019 | Nov2019 | Feb2020 | May2020 | Aug2020 | Nov2020 | Feb2021 | May2021 | Aug2021 | Nov2021 | Feb2022 | May2022 | Aug2022 | Nov2022 | Feb2023 | May2023 | Aug2023 | Nov2023 | Feb2024 | May2024 | Aug2024 | Nov2024 | Feb2025 | May2025 | Aug2025 | Nov2025 | Feb2026 | May2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||||
| EBT Margin | -282.46% | -509.17% | -442.09% | -397.14% | -423.58% | -688.74% | -321.11% | -79.14% | -200.26% | -276.77% | -249.79% | -367.65% | -388.26% | -440.69% | -305.38% | -96.93% | -1,094.77% | -576.13% | -1,394.34% | -993.10% | ||||||||
| EBIT Margin | -282.84% | -513.16% | -444.28% | -399.89% | -432.93% | -717.82% | -338.60% | -87.25% | -216.67% | -299.06% | -272.65% | -401.42% | -433.83% | -486.73% | -340.67% | -109.68% | -1,157.65% | -612.03% | -1,479.45% | -1,041.73% | ||||||||
| EBITDA Margin | -276.01% | -502.79% | -433.98% | -388.51% | -419.03% | -693.96% | -324.79% | -81.07% | -206.10% | -286.30% | -260.32% | -382.15% | -414.82% | -467.54% | -327.94% | -104.59% | -1,131.96% | -596.41% | -1,444.32% | -1,016.80% | ||||||||
| Operating Margin | -282.84% | -513.16% | -444.28% | -399.89% | -432.93% | -717.82% | -338.60% | -87.25% | -216.67% | -299.06% | -272.65% | -401.42% | -433.83% | -486.73% | -340.67% | -109.68% | -1,157.65% | -612.03% | -1,479.45% | -1,041.73% | ||||||||
| Net Margin | -281.26% | -509.76% | -442.09% | -397.14% | -423.58% | -688.74% | -321.11% | -79.14% | -200.26% | -276.77% | -250.33% | -368.39% | -388.91% | -440.75% | -305.38% | -98.66% | -1,094.77% | -576.13% | -1,394.34% | -990.10% | ||||||||
| FCF Margin | -310.54% | -429.60% | -479.18% | -312.31% | -460.81% | -597.38% | -399.91% | -63.73% | -236.05% | 159.01% | -270.33% | -344.38% | -353.70% | -382.84% | -349.93% | -149.44% | -761.29% | -537.40% | -1,166.97% | -1,089.34% | ||||||||
| Efficiency | ||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 505.53M | 484.92M | 457.25M | 416.01M | 426.82M | 438.05M | 393.46M | 360.39M | 329.41M | 331.90M | 334.14M | 411.85M | 512.32M | 591.47M | 642.19M | 603.30M | 557.01M | 605.30M | 662.13M | 585.84M | ||||||||
| Equity AverageEquity Avg. | 386.70M | 358.76M | 324.11M | 286.33M | 304.64M | 323.12M | 288.87M | 266.99M | 246.87M | 217.16M | 184.62M | 269.72M | 373.77M | 451.92M | 503.95M | 464.26M | 409.93M | 455.50M | 509.82M | 441.76M | ||||||||
| Asset Utilization RatioAsset Util. | 0.06 | 0.06 | 0.08 | 0.09 | 0.09 | 0.09 | 0.11 | 0.17 | 0.21 | 0.23 | 0.24 | 0.15 | 0.11 | 0.09 | 0.09 | 0.15 | 0.15 | 0.14 | 0.11 | 0.06 | ||||||||
| Valuation | ||||||||||||||||||||||||||||
| Price to SalesP/S | 49.38 | 43.27 | 21.11 | 11.74 | 18.90 | 15.13 | 10.73 | 7.91 | 6.01 | 3.94 | 7.50 | 16.27 | 29.96 | 30.75 | 20.88 | 9.19 | 8.58 | 21.43 | 23.01 | 50.09 | ||||||||
| Price to BookP/B | 3.82 | 3.76 | 2.37 | 1.70 | 2.17 | 1.92 | 1.63 | 1.85 | 1.76 | 1.51 | 3.60 | 2.73 | 4.49 | 3.18 | 2.45 | 1.82 | 1.93 | 3.34 | 3.43 | 4.57 | ||||||||
| Enterprise Value | 1,090.38M | 991.53M | 463.30M | 157.18M | 397.16M | 275.32M | 170.26M | 200.85M | 153.43M | 15.12M | 557.03M | 570.48M | 1,242.45M | 1,067.92M | 628.15M | 326.71M | 289.16M | 1,207.02M | 1,110.56M | 1,398.21M | ||||||||
| Market Capitalization | 1,434.28M | 1,287.23M | 725.28M | 454.45M | 741.63M | 584.46M | 447.40M | 482.03M | 412.28M | 303.03M | 606.84M | 1,013.62M | 1,690.50M | 1,677.50M | 1,177.83M | 812.49M | 717.99M | 1,799.96M | 1,651.30M | 1,841.74M | ||||||||
| Price to FCFP/FCF | ||||||||||||||||||||||||||||
| EV to FCF | ||||||||||||||||||||||||||||
| EV to CFO | ||||||||||||||||||||||||||||
| Return Ratios | ||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -282.84% | -513.16% | -444.28% | -399.89% | -432.93% | -717.82% | -338.60% | -87.25% | -216.67% | -299.06% | -272.65% | -401.42% | -433.83% | -486.73% | -340.67% | -109.68% | -1,157.65% | -612.03% | -1,479.45% | -1,041.73% | ||||||||
| Return on Capital Employed [ROCE]ROCE | -21.97% | -28.16% | -34.79% | -45.26% | -48.18% | -50.05% | -56.02% | -57.31% | -59.13% | -63.31% | -63.82% | -54.10% | -45.47% | -42.98% | -41.77% | -43.67% | -56.30% | -55.06% | -55.32% | -70.29% | ||||||||
| Return on Assets [ROA]ROA | -19.67% | -24.16% | -29.62% | -37.13% | -40.14% | -41.17% | -45.38% | -43.69% | -45.14% | -43.37% | -43.32% | -40.06% | -34.54% | -32.73% | -32.45% | -34.36% | -43.95% | -43.69% | -44.60% | -58.27% | ||||||||
| Return on Equity [ROE]ROE | -25.71% | -32.66% | -41.79% | -53.94% | -56.24% | -55.82% | -61.81% | -58.97% | -60.24% | -66.29% | -78.39% | -61.18% | -47.35% | -42.83% | -41.35% | -44.66% | -59.71% | -58.06% | -57.92% | -77.27% |
Pull Nurix Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NRIX&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NRIX", "statement": "Ratios", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NRIX&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();